Amneal Pharmaceuticals, Inc. announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company?s total number of commercial injectable products available for the U.S. institutional market to over 40. The growth of Amneal?s broad injectables portfolio will help address shortages of critical products where there may be little or no clinical alternative, including in key categories such as oncology. The American Society of Health System Pharmacists (ASHP) currently lists 323 active U.S. drug shortages, with about half representing injectables.

Notably, three of Amneal?s six new injectable products are currently on the ASHP drug shortage list. With these new launches, Amneal now provides 13 injectables that are on the ASHP shortage list. Amneal?s second quarter 2024 injectable product launches: Product launch: PEMRYDI RTU; Dosage form: Vial; ASHP drug shortage: No; Product launch: Atropine sulfate; Dosage form: Prefilled syringe; ASHP drug shortage: Yes; Product launch: Docetaxel; Dosage form: Injection; ASHP drug shortage: Yes; Product launch: Foscarnet; Dosage form: IV bag; ASHP drug shortage: No; Product launch: Methylprednisolone acetate; Dosage form: Multi-dose vial; ASHP drug shortage: Yes; Product launch: Calcium gluconate; Dosage form: Vial; ASHP drug shortage: No;.

Amneal has tripled its injectables capacity to 60 million units across four manufacturing facilities over the past few years and expects to have over 60 commercial injectable products in 2025. In particular, the Company is launching branded oncology 505(b)(2) products such as PEMRYDI RTU. These injectables are new, ready-to-use presentations that can improve pharmacy efficiency by reducing clinician steps.

Amneal expects to launch two to three new 505(b)(2) injectables per year going forward.